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In recent years, peptide-based drugs have received significant attention from researchers in 
academia as well as pharmaceutical and biotechnological industries. This has been fuelled in 
part by the availability of recombinant technology, allowing high throughput production of 
such therapeutic peptides. In 2012, six peptides were approved in the US; five of which were 
also approved in the EU [1]. One of the most common peptide drugs is insulin, used in the 
treatment of diabetes. Another peptide carfilzomib is available to treat pituitary and 
gastrointestinal tumours and multiple myelomas [2,3].  
 
Compared to small molecules peptides still present with many challenges such as low 
permeability, poor bioavailability, stability and potency. According to Aoki and co-workers, 
about 95% of peptide based drugs face these challenges and therefore usually discarded 
during pre-clinical and/or clinical trials. One major way of overcoming these challenges is the 
development of suitable peptide delivery systems [2]. The parenteral route has traditionally 
been used to deliver peptides. Compared to the gastrointestinal route, this route delivers 
peptides directly into the bloodstream, thereby avoiding denaturing by stomach acid and 
peptidase enzymes present in the digestive tract [4] as well as bypassing first pass liver 
metabolism. However, peptides have relatively short half-lives and therefore require repeat 
injections which are invasive and painful leading to poor patient compliance. In addition, 
parenteral injections generally require trained personnel for effective and safe administration. 
It is our view that traditional (parenteral injections) means of delivering large molecules such 
as peptide drugs will most likely disappear or at best used in emergency situations such as 
comatose patients, once cheaper and efficient alternatives become available routinely 
available. Chitosan based films, for sustained buccal drug delivery presents such a unique 
opportunity for achieving this objective and therefore represents a new era in peptide 
therapeutics. 
 
Though the transdermal route has the advantages of the parenteral route and does not need 
trained personnel, it can cause localized irritation, itching, oedema, and erythema [4]. In our 
opinion, if there is one route that is robust in providing sustained peptide drug delivery to 
achieve a relatively rapid systemic bioavailability in a controlled way, it is the buccal 
mucosa. The oral mucosa presents more advantages than the transdermal route in the delivery 
of peptides, providing a more comfortable route of administration with better patient 
compliance. Compared to other mucosal sites (i.e. intestinal, rectal and nasal); the oral 
mucosa possesses higher vascularity, less enzyme activity and are less susceptible to irritation 
and damage.   
 
The oral mucosa route can be employed for both local and systemic administration of drugs. 
Systemic administration of drugs (including peptides) can be administered by either buccal or 
sublingual routes of administration. These routes exhibit different modes of delivery with the 
sublingual providing more rapid penetration across the mucosa while the buccal mucosa can 
be utilized to achieve a more sustained release profile. As a result, the buccal mucosa has 
been extensively investigated as an important route for delivery of high molecular weight 
drugs such as peptides. Therefore, the buccal mucosa has become a major alternative to 
parenteral route in the administration and delivery of peptide drugs [5]. Obviously any 
successful drug administration via a particular route requires a suitable drug delivery matrix 
which we believe can be found in chitosan. Here, we focus on chitosan based films as a 
suitable matrix and which we suggest represents a potential new era of sustained delivery of 
peptide based drugs. The question is whether such as system provides significant novelty at 
least in matching the performance of parenteral injections and be robust enough to use 
various age groups spanning paediatric, young adult, adult and geriatric populations. We 
believe it does and though uptake by the industry and regulatory authorities remain slow, this 
could be achieved in the not too distant future. 
 
Formulation of conventional dosage forms for buccal drug delivery is affected by 
physiological challenges of the oral cavity. These challenges include the washing effect of 
saliva and poor retention of the formulations on the mucosa surface resulting in unexpected 
drug distribution and less contact period. To achieve better performance, the formulation 
must be optimised to ensure prolonged residence in the buccal area as well as improved drug 
permeation which ensures increased bioavailability. This can be achieved by introducing 
different additives such as mucoadhesive polymers, penetration enhancers and enzyme 
inhibitors [5,6]. These agents are incorporated to help maintain prolonged contact with the 
site of absorption, optimize permeation of drug and inhibit enzyme activities. Generally, 
buccal dosage forms can be divided into four groups; liquids [7]; semi-solids [8]; solids such 
as tablets [9], wafers [10-13], films [14], nano-particulates embedded within films [15,16], 
and sprays [6].  
 
Buccal films are novel relevant solid pharmaceutical formulations based on their versatility 
(both local and systemic drug administration). Their size and thin nature allow ease of 
handling and application, potentially promoting patience compliance. Since they are normally 
prepared from film forming mucoadhesive polymers which attach to the mucosa of the buccal 
region, they can be designed to release drugs (peptides) with a predictable controlled 
(sustained) release profile. Polymers used in the formulation of buccal films are mainly 
hydrophilic which interact with mucin found on the buccal mucosa when swollen. These 
polymers include; chitosan, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose 
and poly (vinyl pyrrolidone) [17]. Based on their surface charge, mucoadhesive polymers can 
be classified as anionic, cationic and non-ionic polymers, with anionic and cationic polymers 
showing better mucoadhesive performance than non-ionic counterparts [6]. 
 
Before exploring this further, it is important to note that a novel buccal delivery system for 
systemic effect of a therapeutic peptide is required to make intimate contact with the buccal 
mucosa, to assure prolonged residence, overcome local peptidase activity and eventual drug 
permeation and bioavailability. Is there a delivery system that is uniquely placed to achieve 
such multi-faceted objective? It is our firm belief that a solution could be found in chitosan 
based films.  
 
Chitosan is a non-toxic biodegradable polymer that is extensively used in the pharmaceutical, 
food and clinical context. It is a cationic polysaccharide formed by the de-acetylation of 
chitin [6], which is the major component of the shells of organisms such as prawns and cell 
walls of fungi such as aspergillus. Chitin is made up of β-(1,4)-linked N-acetyl-glucosamine 
homopolymer units whereas chitosan is made up of glucosamine and N-acetyl-glucosamine 
copolymers. Chitosan derives its cationic nature the free amino group, which allows reaction 
with many anionic polymers. Different researchers have demonstrated the use of chitosan and 
its derivatives to formulate matrices for buccal delivery of peptides and proteins [10 -13] and 
been found to enhance drug absorption through mucosae without damaging the biological 
system. The pH sensitivity, coupled with the reactivity of the primary amine group of 
chitosans allows easy functionalization which can be tailored for specific applications 
including sustained drug delivery via the buccal mucosa [18]. The amino group of chitosan 
contributes to functional characteristics such as controlled drug release, mucoadhesion, 
penetration enhancement, transfection efflux pump inhibition and in situ gelation [19]. 
Chitosan formulations, including films, have therefore attracted significant attention as novel 
drug delivery systems.  
 
We propose that the unique and functional properties of chitosan, coupled with its matrix 
forming ability can be utilized in formulating buccal (matrix) films for the controlled 
(sustained) release of peptides. In our informed opinion, this is significant given the fact that 
though the buccal mucosa represents a suitable alternative to parenteral injections, certain 
inherent factors limit the absorption of drugs. These challenges include the limited absorption 
area compared to the skin, barrier properties (especially to large molecules such as peptides), 
involuntary swallowing of dosage forms and continuous dilution of dissolved drugs by saliva.  
 
Chitosan films [20] may be prepared from either solvent casting [14] or hot melt extrusion 
technique [17] with the former being the most common due to ease of preparation and low 
cost of production. It has been shown that increased chitosan amounts in chitosan/gelatine 
films allowed the lowest percent water-uptake ability and the highest in vivo residence time in 
the buccal cavity [21]. Cui et al., [22] showed the potential of chitosan based films to deliver 
insulin through the buccal mucosa route and they reported a high bioavailability of 17% 
within 5 hours compared with subcutaneous insulin. Giovino and co-workers demonstrated 
the use of insulin loaded nanoparticles incorporated into chitosan based films for sustained 
release of the peptide [15]. The use of chitosan films yielded a 1.8-fold enhancement of ex 
vivo insulin permeation via EpiOralTM buccal tissue construct relative to the pure drug [16]. 
 
In looking into the near future, the desire for a simple but efficient formulation that can 
deliver peptides in a sustained manner without the pain of injections will be a key driving 
force for developing novel peptide delivery systems. It is our view that chitosan based films 
for administration via the buccal mucosa fulfils this criteria and represents a new era in 
buccal drug delivery. This must be keenly followed, though much remains to be achieved to 





1  Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. 
Drug Disc. Today. 18(17–18), 807-817 (2013). 
2  Aoki K, Alles N, Soysa N, Ohya K. Peptide-based delivery to bone. Adv. Drug Del. 
Rev. 64(12), 1220-1238 (2012). 
3  Torchilin V. Intracellular delivery of protein and peptide therapeutics. Drug Disc. 
Today: Tech. 5(2–3), e95-e103 (2008). 
4  Herwadkar A, Banga AK. Peptide and protein transdermal drug delivery. Drug Disc 
Today: Tech, 9(2), e147-e154 (2012). 
5  Rossi S, Sandri G, Caramella CM. Buccal drug delivery: A challenge already won? 
Drug Disc. Today: Tech. 2(1), 59-65 (2005) 
6  Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J. Contr. 
Rel. 153(2), 106-116 (2011). 
7  McMullan J, Sasson C, Pancioli A, Silbergleit R, Midazolam Versus Diazepam for 
the Treatment of Status Epilepticus in Children and Young Adults: A Meta-analysis.  
Acad. Emerg. Med. 17 (6), 575 – 582 (2010). 
8  Fini A, Bergamante V, Ceschel GC. Mucoadhesive Gels Designed for the Controlled 
Release of Chlorhexidine in the Oral Cavity. Pharmaceutics. 3, 665-679 (2011). 
9  Lalla RV, Bensadoun, R-J. Miconazole mucoadhesive tablet for oropharyngeal 
candidiasis.  Expert Rev. Anti-infect. Ther. 9 (1), 13-17 (2011). 
10  Ayensu I, Mitchell JC, Boateng JS. In vitro characterisation of chitosan based 
xerogels for potential buccal delivery of proteins. Carbo. Polym. 89(3), 935-941 
(2012). 
11  Ayensu I, Mitchell JC, Boateng JS. Effect of membrane dialysis on characteristics of 
lyophilised chitosan wafers for potential buccal delivery of proteins. Int. J. Biol. 
Macromol. 50 (4), 905-909. (2012). 
12  Boateng JS, Ayensu I. Preparation and characterization of laminated thiolated 
chitosan-based freeze-dried wafers for potential buccal delivery of macromolecules. 
Drug Dev. Ind. Pharm. 1-8. (doi:10.3109/03639045.2014.884126). (Posted online 10 
Feb 2014). 
13  Boateng JS, Mitchell JC, Pawar HV, Ayensu I. Physico-chemical characterisation and 
in-vitro / ex vivo permeation studies of insulin loaded thiolated chitosan xerogels. 
Pep. Prot. Lett. (In Press) (2014). 
 
14  Kianfar F, Chowdhry BZ, Antonijevic MD, Boateng JS. Novel films for drug delivery 
via the buccal mucosa using model soluble and insoluble drugs. Drug Dev. Ind. 
Pharm. 38 (10), 1207-1220 (2012). 
15  Giovino C, Ayensu I, Tetteh J, Boateng JS. Development and characterisation of 
chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a 
potential approach for buccal delivery of macromolecules. Int. J. Pharm. 428 (1-2), 
143-151. (2012). 
16  Giovino C, Ayensu I, Tetteh J, Boateng JS. An integrated buccal delivery system 
combining chitosan films impregnated with peptide loaded PEG-b-PLA nanoparticles. 
Coll. Surf. B: Biointerf. 112(0), 9-15 (2013). 
17  Morales JO, McConville JT. Manufacture and characterization of mucoadhesive 
buccal films. Eur. J. Pharm. Biopharm. 77(2), 187-199 (2011). 
18  Bernkop-Schnürch A. Chitosan and its derivatives: potential excipients for peroral 
peptide delivery systems.  Int. J. Pharm. 194(1), 1-13 (2000). 
19  Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur. J. 
Pharm. Biopharm. 81(3), 463-469 (2012). 
20  Kim KM, Son JH, Kim SK, Weller CL, Hanna MA. Properties of chitosan films as a 
function of pH and solvent type.  J. Food Sci. 71, 119–124 (2006). 
21  Abruzzo A, Bigucci F, Cerchiara T, Cruciani F, Vitali B, Luppi B. Mucoadhesive 
chitosan/gelatin films for buccal delivery of propranolol hydrochloride. Carbo. 
Polym. 87, 581– 588 (2012). 
22  Cui F, He C, He M, Tang C, Yin L, Qian F, Yin C. Preparation and evaluation of 
chitosan-ethylenediaminetetraacetic acid hydrogel films for the mucoadhesive 
transbuccal delivery of insulin. J. Biomed. Mater. Res. Part A. 89A, 1063–1071. 
(2009). 
